In vitro, ICOS/ICOSL blockade significantly reduced the generation of MM cell‐induced inhibitory CD4+ Treg cells,55, 56 and lenalidomide, a clinically approved anti‐MM immunomodulatory drug, could inhibit ICOSL expression in MM cells57 and enhance PD‐1/PD‐L1 blockade‐induced anticancer immunity in MM patients.58 This evidence concerns the gene CD4 and Miyoshi myopathy.